Sera Prognostics (NASDAQ:SERA) CFO Austin Aerts Sells 5,440 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 5,440 shares of Sera Prognostics stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total transaction of $11,315.20. Following the sale, the chief financial officer owned 303,227 shares of the company’s stock, valued at approximately $630,712.16. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Price Performance

Shares of Sera Prognostics stock opened at $2.00 on Thursday. Sera Prognostics, Inc. has a 1 year low of $1.43 and a 1 year high of $4.09. The firm has a market cap of $78.32 million, a PE ratio of -3.08 and a beta of 0.94. The company has a 50 day simple moving average of $2.03 and a two-hundred day simple moving average of $2.55.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, May 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.07 million. As a group, research analysts anticipate that Sera Prognostics, Inc. will post -0.58 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

A number of hedge funds and other institutional investors have recently modified their holdings of SERA. Qube Research & Technologies Ltd bought a new stake in Sera Prognostics during the 2nd quarter valued at $92,000. Captrust Financial Advisors raised its holdings in Sera Prognostics by 20.0% during the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after buying an additional 100,366 shares during the last quarter. Corient Private Wealth LLC raised its holdings in Sera Prognostics by 73.9% during the 2nd quarter. Corient Private Wealth LLC now owns 100,000 shares of the company’s stock valued at $277,000 after buying an additional 42,500 shares during the last quarter. Vanguard Personalized Indexing Management LLC bought a new stake in Sera Prognostics during the 3rd quarter valued at $38,000. Finally, Caprock Group LLC bought a new stake in Sera Prognostics during the 3rd quarter valued at $108,000. Institutional investors own 54.64% of the company’s stock.

Analysts Set New Price Targets

SERA has been the subject of several research analyst reports. Craig Hallum initiated coverage on Sera Prognostics in a research note on Thursday, June 4th. They set a “buy” rating and a $6.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a research note on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $5.50.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.